Helix BioPharma (TSE:HBP) Reaches New 1-Year High - Should You Buy?

Key Points

• Helix BioPharma shares reached a new 52-week high, trading at C$1.60 with a volume of 1,215 shares during mid-day on Monday.
• The company, which has a market cap of C$121.44 million, focuses on cancer drug development, particularly in the area of immuno-oncology.
• Helix BioPharma's stock has a PE ratio of -1.54 and is currently above its fifty-day moving average of C$1.30.

Helix BioPharma Corp. (TSE:HBP - ) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$1.60 and last traded at C$1.60, with a volume of 1215 shares changing hands. The stock had previously closed at C$1.59.

Helix BioPharma Price Performance

The stock has a market cap of C$121.44 million, a PE ratio of -1.54 and a beta of -0.45. The stock's fifty day moving average is C$1.30 and its 200-day moving average is C$1.03.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.